Tanezumab
Encyclopedia
Tanezumab is a monoclonal antibody
against nerve growth factor
. It was developed by Pfizer
as a treatment for pain.
In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA)
.
Another phase III trial for hip pain in OA was halted in June 2010 when some patients needed hip replacement.
Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.
Robert J. Evans III, MD is board certified, a fellow in the American College of Surgeons, and is currently the principal investigator in the clinical trial evaluating the new drug tanezumab for treating interstitial cystitis. A specialist in painful bladder syndrome, Dr. Evans is a member of the medical advisory board of the Interstitial Cystitis Association and practices medicine with the department of urology at Wake Forest University Baptist Medical Center, Winston-Salem, NC.
Monoclonal antibodies
Monoclonal antibodies are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a unique parent cell....
against nerve growth factor
Nerve growth factor
Nerve growth factor is a small secreted protein that is important for the growth, maintenance, and survival of certain target neurons . It also functions as a signaling molecule. It is perhaps the prototypical growth factor, in that it is one of the first to be described...
. It was developed by Pfizer
Pfizer
Pfizer, Inc. is an American multinational pharmaceutical corporation. The company is based in New York City, New York with its research headquarters in Groton, Connecticut, United States...
as a treatment for pain.
In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA)
Osteoarthritis
Osteoarthritis also known as degenerative arthritis or degenerative joint disease, is a group of mechanical abnormalities involving degradation of joints, including articular cartilage and subchondral bone. Symptoms may include joint pain, tenderness, stiffness, locking, and sometimes an effusion...
.
Another phase III trial for hip pain in OA was halted in June 2010 when some patients needed hip replacement.
Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.
Robert J. Evans III, MD is board certified, a fellow in the American College of Surgeons, and is currently the principal investigator in the clinical trial evaluating the new drug tanezumab for treating interstitial cystitis. A specialist in painful bladder syndrome, Dr. Evans is a member of the medical advisory board of the Interstitial Cystitis Association and practices medicine with the department of urology at Wake Forest University Baptist Medical Center, Winston-Salem, NC.